Patients with cystic fibrosis (CF) suffer from a progressive respiratory failure which leads to the need for lung transplantation (LUTX). Frequently, CF patients have an alteration in the function of the right cardiac ventricle, which is associated to the need for extracorporeal circulation during the LUTX. The use of extracorporeal circulation during LUTX operation is associated with worse short-term outcomes, such as longer need for mechanical ventilation, intensive care unit, hospital stay and graft dysfunction. Levosimendan is an innovative drug that until now has been studied in patients with chronic cardiac failure and may be particularly useful in CF patients. Researchers aim to study the function of the right ventricle extensively by means of a echocardiography, throughout the preoperative course. Once recognized the patients with cardiac dysfunction, they will assess the feasibility and efficacy of the use of Levosimendan to prevent its consequences during LUTX. CF patients undergoing LUTX in the first year of the study will be screened for right ventricle dysfunctions; in the second year will be offered a preoperative Levosimendan treatment. The objectives are to ameliorate diagnosis of right ventricular dysfunction in CF patients and verify its efficacy in preventing intra and per-operatory complications of lung transplantation.